| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
|
J Clin Oncol
|
2007
|
7.45
|
|
2
|
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
|
Lancet Oncol
|
2013
|
6.79
|
|
3
|
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
|
N Engl J Med
|
2014
|
6.76
|
|
4
|
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.
|
J Clin Oncol
|
2009
|
6.51
|
|
5
|
Adjuvant ovarian suppression in premenopausal breast cancer.
|
N Engl J Med
|
2014
|
5.18
|
|
6
|
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
|
Cancer Cell
|
2008
|
4.51
|
|
7
|
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
|
J Natl Cancer Inst
|
2008
|
3.16
|
|
8
|
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
|
J Natl Cancer Inst
|
2003
|
3.16
|
|
9
|
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
|
J Clin Oncol
|
2006
|
3.15
|
|
10
|
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
|
J Clin Oncol
|
2009
|
2.98
|
|
11
|
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?
|
J Natl Cancer Inst
|
2010
|
2.28
|
|
12
|
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
|
J Clin Oncol
|
2008
|
2.10
|
|
13
|
Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.
|
Breast Cancer Res Treat
|
2010
|
1.97
|
|
14
|
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
|
Breast
|
2013
|
1.94
|
|
15
|
Adjuvant endocrine therapy for premenopausal women with early breast cancer.
|
J Clin Oncol
|
2005
|
1.71
|
|
16
|
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy.
|
Blood
|
2006
|
1.69
|
|
17
|
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
|
Cancer Chemother Pharmacol
|
2007
|
1.66
|
|
18
|
Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
|
Breast Cancer Res Treat
|
2008
|
1.62
|
|
19
|
Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa.
|
Chest
|
2004
|
1.62
|
|
20
|
Pathological features and survival outcomes of very young patients with early breast cancer: how much is "very young"?
|
Breast
|
2013
|
1.51
|
|
21
|
Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients.
|
Cancer
|
2004
|
1.48
|
|
22
|
Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.46
|
|
23
|
Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter.
|
Support Care Cancer
|
2007
|
1.42
|
|
24
|
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
|
Breast
|
2012
|
1.39
|
|
25
|
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
|
J Clin Oncol
|
2008
|
1.34
|
|
26
|
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
|
Breast Cancer Res Treat
|
2008
|
1.31
|
|
27
|
Breast phyllodes tumor: a review of literature and a single center retrospective series analysis.
|
Crit Rev Oncol Hematol
|
2013
|
1.30
|
|
28
|
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
|
BMC Cancer
|
2006
|
1.24
|
|
29
|
Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years.
|
Ann Surg
|
2008
|
1.20
|
|
30
|
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.
|
Breast Cancer Res
|
2014
|
1.20
|
|
31
|
Research issues affecting preoperative systemic therapy for operable breast cancer.
|
J Clin Oncol
|
2008
|
1.18
|
|
32
|
Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?
|
Breast Cancer Res Treat
|
2011
|
1.14
|
|
33
|
Invasive lobular breast cancer: subtypes and outcome.
|
Breast Cancer Res Treat
|
2012
|
1.11
|
|
34
|
Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution.
|
Cancer
|
2004
|
1.11
|
|
35
|
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
|
Anticancer Drugs
|
2006
|
1.09
|
|
36
|
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.
|
Clin Cancer Res
|
2009
|
1.07
|
|
37
|
Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.
|
Clin Breast Cancer
|
2012
|
1.05
|
|
38
|
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
|
J Clin Oncol
|
2007
|
1.04
|
|
39
|
Is adjuvant chemotherapy useful for women with luminal a breast cancer?
|
J Clin Oncol
|
2012
|
1.03
|
|
40
|
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
|
J Clin Oncol
|
2012
|
1.03
|
|
41
|
Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women.
|
Breast Cancer Res Treat
|
2013
|
1.02
|
|
42
|
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression.
|
Cancer Chemother Pharmacol
|
2007
|
0.98
|
|
43
|
Results of chest wall resection for recurrent or locally advanced breast malignancies.
|
Breast
|
2007
|
0.97
|
|
44
|
Breast-conserving surgery in 201 very young patients (<35 years).
|
Breast
|
2009
|
0.95
|
|
45
|
HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.
|
Eur J Cancer
|
2007
|
0.95
|
|
46
|
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
|
Clin Breast Cancer
|
2012
|
0.94
|
|
47
|
Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.
|
Clin Breast Cancer
|
2010
|
0.93
|
|
48
|
Prediction of cancer outcome with microarrays.
|
Lancet
|
2005
|
0.91
|
|
49
|
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.
|
Breast
|
2013
|
0.89
|
|
50
|
The clinical relevance of micropapillary carcinoma of the breast: a case-control study.
|
Histopathology
|
2013
|
0.87
|
|
51
|
Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?
|
Ecancermedicalscience
|
2013
|
0.86
|
|
52
|
Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
|
Anticancer Res
|
2004
|
0.86
|
|
53
|
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.
|
Ann Oncol
|
2007
|
0.86
|
|
54
|
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
|
Anticancer Drugs
|
2009
|
0.86
|
|
55
|
Sentinel lymph node biopsy is feasible even after total mastectomy.
|
J Surg Oncol
|
2007
|
0.85
|
|
56
|
Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation.
|
Breast Cancer Res Treat
|
2011
|
0.85
|
|
57
|
Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
|
Breast
|
2008
|
0.85
|
|
58
|
The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
|
Cancer Treat Rev
|
2013
|
0.85
|
|
59
|
Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features.
|
Clin Breast Cancer
|
2004
|
0.85
|
|
60
|
Unnecessary axillary node dissections in the sentinel lymph node era.
|
Eur J Cancer
|
2007
|
0.84
|
|
61
|
Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series.
|
Breast Cancer Res Treat
|
2008
|
0.83
|
|
62
|
Influence of margin status on outcomes in lobular carcinoma: experience of the European Institute of Oncology.
|
Ann Surg
|
2011
|
0.83
|
|
63
|
Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates.
|
Ann Surg Oncol
|
2012
|
0.83
|
|
64
|
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
|
Cancer
|
2007
|
0.83
|
|
65
|
Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
|
Breast Cancer Res Treat
|
2012
|
0.82
|
|
66
|
Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.82
|
|
67
|
Positive axillary sentinel lymph node: is axillary dissection always necessary?
|
Breast
|
2011
|
0.82
|
|
68
|
Focusing on physical function limitations in elderly women surviving cancer: any opportunity for improvement?
|
Nat Clin Pract Oncol
|
2006
|
0.82
|
|
69
|
Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer.
|
Anticancer Res
|
2009
|
0.82
|
|
70
|
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.
|
Breast Cancer Res Treat
|
2009
|
0.81
|
|
71
|
Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis.
|
Support Cancer Ther
|
2006
|
0.81
|
|
72
|
Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
|
Clin Breast Cancer
|
2012
|
0.81
|
|
73
|
Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy.
|
Eur J Nucl Med Mol Imaging
|
2010
|
0.80
|
|
74
|
Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy.
|
Cancer Treat Rev
|
2010
|
0.80
|
|
75
|
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer.
|
Breast
|
2011
|
0.80
|
|
76
|
Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years.
|
Oncologist
|
2009
|
0.79
|
|
77
|
Intrathecal chemotherapy in carcinomatous meningitis from breast cancer.
|
Anticancer Res
|
2003
|
0.78
|
|
78
|
Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group.
|
Support Care Cancer
|
2007
|
0.78
|
|
79
|
Local therapy for breast cancer in malignant lymphoma survivors.
|
Breast
|
2011
|
0.78
|
|
80
|
Video-assisted management of malignant pleural effusion in breast carcinoma.
|
Cancer
|
2006
|
0.77
|
|
81
|
Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
|
Breast J
|
2008
|
0.77
|
|
82
|
Letrozole.
|
Expert Opin Drug Metab Toxicol
|
2010
|
0.77
|
|
83
|
New criteria for selecting elderly patients for breast cancer adjuvant treatment studies.
|
Oncologist
|
2007
|
0.77
|
|
84
|
Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer.
|
Breast Cancer Res Treat
|
2014
|
0.77
|
|
85
|
Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors.
|
Breast
|
2008
|
0.77
|
|
86
|
Tailoring adjuvant treatments for the individual patient with luminal breast cancer.
|
Hematol Oncol Clin North Am
|
2013
|
0.76
|
|
87
|
Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.
|
Breast J
|
2012
|
0.76
|
|
88
|
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.
|
Anticancer Drugs
|
2006
|
0.76
|
|
89
|
Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93.
|
Breast Cancer Res Treat
|
2013
|
0.76
|
|
90
|
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
|
Breast
|
2010
|
0.76
|
|
91
|
Sentinel lymph node biopsy in multicentric breast cancer: five-year results in a large series from a single institution.
|
Ann Surg Oncol
|
2011
|
0.75
|
|
92
|
Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer.
|
Breast
|
2009
|
0.75
|
|
93
|
A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer.
|
Breast
|
2012
|
0.75
|
|
94
|
Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song.
|
J Clin Oncol
|
2005
|
0.75
|
|
95
|
The 6th Milan Breast Cancer Conference, Milan, Italy, 16-18 June 2004.
|
Breast Cancer Res
|
2004
|
0.75
|
|
96
|
Adjuvant chemotherapy in breast cancer: back to the future.
|
Onkologie
|
2003
|
0.75
|
|
97
|
Metronomic chemotherapy in elderly patients: do risks exceed benefits in some patients?
|
Tumori
|
2009
|
0.75
|
|
98
|
PET/CT and breast cancer subtypes.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.75
|
|
99
|
Nonrandomized comparison between concomitant and sequential chemoradiotherapy with anthracyclines in breast cancer.
|
Tumori
|
2015
|
0.75
|
|
100
|
Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer.
|
Breast
|
2006
|
0.75
|
|
101
|
Innovation in care and research: meeting highlights from the seventh Milan Breast Cancer Conference (Milan, 15-17 June, 2005).
|
Breast
|
2006
|
0.75
|
|
102
|
Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer.
|
Breast
|
2010
|
0.75
|